This agreement covers the option for AbbVie to acquire a co-exclusive license for the development, manufacturing and commercialization of reproxalap in the United States. It also includes an option for an exclusive license to those same rights outside of the United States.
This option agreement sets up Aldeyra to receive payments from AbbVie depending on if it exercises those options. That includes a $1 million option fee as well as an upfront payment of $100 million.
To go along with this, Aldeyra Therapeutics is eligible for milestone payments from AbbVie. That could see it gain up to $300 million in milestone payments from regulatory and commercialization actions. Aldeyra will also split profits and losses connected to reproxalap in the U.S. on a 40%/60% basis.
How This Affects ALDX Stock Today
Investors are celebrating today’s news with heavy trading of ALDX stock. As of this writing, more than 31 million shares have changed hands. For comparison, the company’s daily average trading volume is about 1.1 million shares.
ALDX stock is up 40.4% as of Wednesday morning.
There’s plenty more stock market news traders will want to dive into below!
We’re offering up all of the hottest stock market happenings worth reading about on Wednesday! Among that is what’s happening with shares of Polestar Automotive (NASDAQ:PSNY), CRISPR Therapeutics (NASDAQ:CRSP) and WeWork (NYSE:WE) stock today. You can catch up on all of these matters below!
More Wednesday Stock Market News
- PSNY Stock Alert: Piper Sandler Is Pounding the Table on Polestar
- CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
- WE Stock Alert: WeWork Prepares for ‘Imminent’ Bankruptcy
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.